vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and Cadre Holdings, Inc. (CDRE). Click either name above to swap in a different company.
Cadre Holdings, Inc. is the larger business by last-quarter revenue ($167.2M vs $255, roughly 655780.4× Bone Biologics Corp). Cadre Holdings, Inc. runs the higher net margin — 7.0% vs -339596.1%, a 339603.1% gap on every dollar of revenue. On growth, Cadre Holdings, Inc. posted the faster year-over-year revenue change (-5.0% vs -54.1%).
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
RealCadre LLC, commonly Cadre, is an American financial technology company that provides individuals and institutions direct access to real estate investment properties, including commercial properties based in New York. The business and financial press describe it as a platform that "makes the real estate market more like the stock market" by allowing investors to select the individual transactions in which they participate, while investing a smaller amount than would be required to fully fu...
BBLG vs CDRE — Head-to-Head
Income Statement — Q1 2024 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $255 | $167.2M |
| Net Profit | $-866.0K | $11.7M |
| Gross Margin | — | 43.4% |
| Operating Margin | -354327.8% | 12.2% |
| Net Margin | -339596.1% | 7.0% |
| Revenue YoY | -54.1% | -5.0% |
| Net Profit YoY | 76.7% | -9.6% |
| EPS (diluted) | $-1.31 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $167.2M | ||
| Q3 25 | — | $155.9M | ||
| Q2 25 | — | $157.1M | ||
| Q1 25 | — | $130.1M | ||
| Q4 24 | — | $176.0M | ||
| Q3 24 | — | $109.4M | ||
| Q2 24 | — | $144.3M | ||
| Q1 24 | $255 | $137.9M |
| Q4 25 | — | $11.7M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $12.2M | ||
| Q1 25 | — | $9.2M | ||
| Q4 24 | — | $13.0M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | $-866.0K | $6.9M |
| Q4 25 | — | 43.4% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 43.9% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 40.6% | ||
| Q1 24 | — | 41.8% |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | — | 5.0% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | -354327.8% | 8.7% |
| Q4 25 | — | 7.0% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | -339596.1% | 5.0% |
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | — | $0.30 | ||
| Q1 25 | — | $0.23 | ||
| Q4 24 | — | $0.32 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $0.31 | ||
| Q1 24 | $-1.31 | $0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $122.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7M | $317.8M |
| Total Assets | $3.8M | $770.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $122.9M | ||
| Q3 25 | — | $150.9M | ||
| Q2 25 | — | $137.5M | ||
| Q1 25 | — | $133.4M | ||
| Q4 24 | — | $124.9M | ||
| Q3 24 | — | $93.0M | ||
| Q2 24 | — | $105.9M | ||
| Q1 24 | — | $87.1M |
| Q4 25 | — | $317.8M | ||
| Q3 25 | — | $340.4M | ||
| Q2 25 | — | $332.5M | ||
| Q1 25 | — | $317.6M | ||
| Q4 24 | — | $311.5M | ||
| Q3 24 | — | $300.3M | ||
| Q2 24 | — | $299.4M | ||
| Q1 24 | $3.7M | $270.7M |
| Q4 25 | — | $770.0M | ||
| Q3 25 | — | $792.1M | ||
| Q2 25 | — | $794.4M | ||
| Q1 25 | — | $656.3M | ||
| Q4 24 | — | $652.7M | ||
| Q3 24 | — | $616.6M | ||
| Q2 24 | — | $620.6M | ||
| Q1 24 | $3.8M | $599.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $21.3M |
| Free Cash FlowOCF − Capex | — | $18.0M |
| FCF MarginFCF / Revenue | — | 10.7% |
| Capex IntensityCapex / Revenue | — | 2.0% |
| Cash ConversionOCF / Net Profit | — | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $22.5M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | $17.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | $-1.3M | $2.1M |
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $21.6M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $16.1M | ||
| Q4 24 | — | $22.4M | ||
| Q3 24 | — | $-6.2M | ||
| Q2 24 | — | $9.1M | ||
| Q1 24 | — | $794.0K |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | -5.7% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 2.05× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 1.88× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | -1.43× | ||
| Q2 24 | — | 0.89× | ||
| Q1 24 | — | 0.31× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBLG
Segment breakdown not available.
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
